<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37665981</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>229</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Condition After SARS-CoV-2 Infections During the Omicron Surge vs the Delta, Alpha, and Wild Type Periods in Stockholm, Sweden.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>136</EndPage><MedlinePgn>133-136</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiad382</ELocationID><Abstract><AbstractText>Little is known about the post-COVID-19 condition (PCC) after infections with different SARS-CoV-2 variants. We investigated the risk of PCC diagnosis after primary omicron infections as compared with preceding variants in population-based cohorts in Stockholm, Sweden. When compared with omicron (n = 215 279, 0.2% receiving a PCC diagnosis), the adjusted hazard ratio (95% CI) was 3.26 (2.80-3.80) for delta (n = 52 182, 0.5% PCC diagnosis), 5.33 (4.73-5.99) for alpha (n = 97 978, 1.0% PCC diagnosis), and 6.31 (5.64-7.06) for the wild type (n = 107 920, 1.3% PCC diagnosis). These findings were consistent across all subgroup analyses except among those treated in the intensive care unit.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hedberg</LastName><ForeName>Pontus</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3153-098X</Identifier><AffiliationInfo><Affiliation>Department of Medicine Huddinge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naucl&#xe9;r</LastName><ForeName>Pontus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021-04809</GrantID><Agency>Swedish Research Council</Agency><Country/></Grant><Grant><GrantID>101046016</GrantID><Agency>European Union's Horizon Europe Research and Innovation Programme</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post&#x2013;COVID-19 condition</Keyword></KeywordList><CoiStatement>Potential conflicts of interest . Both authors: No reported conflicts. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>15</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>16</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37665981</ArticleId><ArticleId IdType="pmc">PMC10786247</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad382</ArticleId><ArticleId IdType="pii">7259851</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus. 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 19 June 2023.</Citation></Reference><Reference><Citation>Munblit D, O&#x2019;Hara ME, Akrami A, Perego E, Olliaro P, Needham DM. Long COVID: aiming for a consensus. Lancet Respir Med 2022; 10:632&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067938</ArticleId><ArticleId IdType="pubmed">35525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F-H, Jia Y-J, Zhao D-Y, et al. . Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 omicron and delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019&#x2013;positive patients. Clin Microbiol Infect 2023; 29:835&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10023211</ArticleId><ArticleId IdType="pubmed">36934872</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, Kristoffersen DT, Dell&#x2019;Isola A, et al. . Post-COVID medical complaints following infection with SARS-CoV-2 omicron vs delta variants. Nat Commun 2022; 13:7363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Armando F, Beythien G, Kaiser FK, et al. . SARS-CoV-2 omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. Nat Commun 2022; 13:3519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207884</ArticleId><ArticleId IdType="pubmed">35725735</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, et al. . COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386:1532&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Granath F, Bruchfeld J, et al. https://doi.org/10.21203%2Frs.3.rs-1804130%2Fv1 Post COVID-19 condition diagnosis: a population-based cohort study of occurrence, associated factors, and healthcare use by severity of acute infection. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877994</ArticleId><ArticleId IdType="pubmed">36478477</ArticleId></ArticleIdList></Reference><Reference><Citation>
Public Health Agency of Sweden . Intensivv&#xe5;rdade fall av covid-19 under tidsperioder med olika dominerande virusvarianter.https://www.folkhalsomyndigheten.se/globalassets/statistik-uppfoljning/smittsamma-sjukdomar/veckorapporter-covid-19/2023/specialavsnitt-intensivvardade-covid-19-2023.pdf. Accessed 19 June 2023.</Citation></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 2023; 380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. New long COVID cases decline with omicron. Science 2023; 379:1174&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">36952419</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock MD, Chew RF, Preiss AJ, et al. . Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun 2023; 14:2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . New-onset, self-reported long COVID after coronavirus (COVID-19) reinfection in the UK.https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/newonsetselfreportedlongcovidaftercoronaviruscovid19reinfectionintheuk/23february2023. Accessed 11 August 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>